Navigation Links
SAFC Pharma Expands Its Pharmorphix Solid State Chemistry Services
Date:1/30/2008

ST. LOUIS, Jan. 30 /PRNewswire-FirstCall/ -- SAFC(R), a member of the Sigma-Aldrich(TM) Group (Nasdaq: SIAL), has announced the second-phase of a $600,000 expansion of its solid-state services Pharmorphix(TM) research facility in Cambridge, UK, adding 7,500 sq. ft. of laboratory capacity to support this fast growing business within its SAFC Pharma(TM) focus area (http://www.safc-pharmorphix.com).

Solid-form characterization and research enhances understanding and allows modification of the physical properties of active pharmaceutical ingredients (APIs) to ensure patient benefit, optimize product development and protect intellectual property. As part of a multi-phase development program the additional, fully refitted space is scheduled for completion in the first quarter, 2008 and will augment the current 12,500 sq. ft. facility. The development includes office reorganization and will facilitate installation later this year of additional state-of-the-art spectroscopic and diffraction equipment.

SAFC Pharma Vice President of Manufacturing and European Operations, Michael Harris commented, "As new drugs and the regulatory climate continues to become more complex, testing analysis and optimization of APIs plays an increasingly key role in drug development. Through our Pharmorphix solid-state research services SAFC Pharma is a recognized and capable player in this complex field. The additional facilities reinforce our commitment to support customers in niche technologies and is expected to support SAFC business growth from Europe, the US and, increasingly, from Asia Pacific".

SAFC Pharma is a trusted leader for development and manufacturing of complex small molecule APIs and biologic drug products. This new expansion follows a recently announced $12 million expansion of SAFC Pharma's viral product manufacturing facility in Carlsbad, CA and the Pharmorphix services launch in the U.S. at its flagship high-potent manufacturing facility in Madison, WI, with new XRPD (X-ray Powder Diffraction) analytical equipment. Other recently announced investments include a $10 million expansion of commercial-scale APIs manufacturing and storage capacity, respectively, at Arklow, Ireland and Buchs, Switzerland, a $29 million potent-fermentation expansion in Jerusalem, Israel and a high-potent API conjugation suite at its St Louis, MO manufacturing campus.

About SAFC: SAFC(R) is the custom manufacturing and services group within Sigma-Aldrich that focuses on high-purity inorganics for high technology applications, cell culture products and services for biopharmaceutical manufacturing, biochemical production and the manufacturing of complex, multi-step organic synthesis of APIs and key intermediates. SAFC has manufacturing facilities around the world dedicated to providing manufacturing services for companies requiring a reliable partner to produce their custom manufactured materials. SAFC has four focus areas -- SAFC Pharma(TM), SAFC Supply Solutions(R), SAFC Biosciences(TM), and SAFC Hitech(TM) -- and had annual sales of nearly $500 million in 2006. SAFC is one of the world's 10 largest fine chemical businesses. For more information about SAFC visit http://www.safcglobal.com.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.

SAFC(R) and SAFC Supply Solutions(R) are registered trademarks of Sigma-Aldrich Biotechnology L.P.

Sigma-Aldrich(TM), SAFC Pharma(TM), SAFC Biosciences(TM) and SAFC Hitech(TM) are trademarks of Sigma-Aldrich Biotechnology L.P.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... ... Responsible dental care hinges on regular brushing of the teeth. However, just brushing ... inspired an inventor from Las Vegas, Nev., to design the BRUSH PROPER. , ... bad techniques of brushing the teeth in order to prevent cavities," he said. "Children ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... on the perils of heroin that was watched live by 1 million viewers ... I. duPont-Columbia University Award. , ASU students at the Walter Cronkite School of ...
(Date:12/2/2016)... ... 02, 2016 , ... More than 100 business, civic, community ... attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This inaugural event, hosted ... operating support to UNCF-member institutions, including Miles College, Oakwood University, Tuskegee University, Stillman ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and ... of those affected by autism spectrum disorder (ASD) and other developmental disabilities. The group, ... will give parents and other caregivers the opportunity to share stories and advice, seek ...
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with constant ... works for them. When an inventor from Suisun City, Calif., was unsuccessful in finding ... it with others. , He developed a prototype for PRO GO MASSAGE to relieve ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... , Dec. 4, 2016 Blueprint Medicines ... discovering and developing targeted kinase medicines for patients ... its ongoing Phase 1 trial evaluating BLU-285, an ... advanced systemic mastocytosis (SM). Blueprint Medicines is developing ... D816V mutant KIT. Approximately 90 to 95 percent ...
(Date:12/4/2016)... SAN DIEGO , Dec. 3, 2016 Johnson ... filed on behalf of purchasers of Zimmer Biomet Holdings, Inc. ... September 7, 2016 through October 31, 2016 (the "Class Period"). ... It designs, manufactures, and markets orthopaedic reconstructive products, such as ... ...
(Date:12/4/2016)... NEW ORLEANS , Dec. 2, 2016  Former Attorney ... Foti, Jr., Esq. , a partner at the law firm ... has commenced an investigation into Lannett Company, Inc. (NYSE: ... Bloomberg published an article titled "U.S. Charges in ... an "antitrust investigation by the Justice Department, begun about two ...
Breaking Medicine Technology: